# P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma

> **NCT04960579** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Poseida Therapeutics, Inc.** · enrollment: 275 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** P-BCMA-ALLO1 CAR-T cells
- **DRUG:** Rimiducid
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT04960579
- **Lead sponsor:** Poseida Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-05-05
- **Primary completion:** 2029-03
- **Final completion:** 2042-03
- **Target enrollment:** 275 (ESTIMATED)
- **Last updated:** 2026-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04960579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04960579, "P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04960579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*